Research programme: cannabis-based therapeutics - NEMUS Bioscience

Drug Profile

Research programme: cannabis-based therapeutics - NEMUS Bioscience

Alternative Names: Cannabidiol derivatives - NEMUS; Cannabionoid therapeutics - NEMUS; CBD derivatives - NEMUS; NB 1111; NB 1222; NB 2111; NB 2221; NB 2222; NB 23R1; NB 3111; NB 31R1; NB 51R1; NB3000 series; THC-valine-hemisuccinate; UM 5070

Latest Information Update: 06 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NEMUS Bioscience; University of Mississippi
  • Class Analgesics; Antibacterials; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Eye disorder therapies; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chemotherapy-induced nausea and vomiting; Methicillin-resistant Staphylococcus aureus infections; Muscle spasticity; Open-angle glaucoma; Pain; Peripheral nervous system diseases
  • Research Anxiety disorders; Diabetic retinopathy; Dry eyes; Epilepsy; Macular degeneration; Uveitis

Most Recent Events

  • 05 Feb 2018 Teewinot Life Sciences Corporation has patent protection for CannSynthesis™ technology in USA
  • 22 Jan 2018 Teewinot Life Sciences Corporation has patents pending for CannSynthesis™ technology worldwide
  • 22 Jan 2018 Teewinot Life Sciences Corporation receives patent allowance for CannSynthesis™ technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top